CRISPR Therapeutics Stock: Is It a Bargain Buy Right Now?

Finding a quality mid-cap stock to invest in can lead to huge returns for investors down the road. These are the types of companies that are still in their early growth stages and that can possess significant upside. There is some unavoidable risk and uncertainty, and the key is to ensure you don’t take on too much.

One stock that’s been on my watch list for a while is **CRISPR Therapeutics **(CRSP +2.01%). The company has an intriguing business, as not only could it generate a lot of revenue in the future, but it may also be a potential acquisition target. It has an approved gene-editing therapy, Casgevy, and there’s hope that CRISPR may obtain additional approvals in the future.

This year, the healthcare stock is down 9% after recently announcing an offering. Could it be a bargain buy right now?

Image source: Getty Images.

The company recently completed a private offering

On March 16, CRISPR announced that it completed a private offering of convertible senior notes, raising net proceeds of $585.2 million, which it will use for general corporate purposes. Issuing convertible notes is dilutive as they can be converted into equity in the future, and this offering has had a negative impact on CRISPR’s share price; in the past month, the stock has declined by 12%.

The offering also highlights the growing need for CRISPR to raise cash in order to grow its business. The company generated just $3.5 million in revenue last year (all from grants), and its net loss of $581.6 million grew from $366.3 million in the previous year. The company shares in the profits on Casgevy with its development partner, Vertex Pharmaceuticals, so despite the therapy generating $116 million in revenue last year, it didn’t result in a big improvement on CRISPR’s bottom line.

Expand

NASDAQ: CRSP

CRISPR Therapeutics

Today’s Change

(2.01%) $0.93

Current Price

$47.17

Key Data Points

Market Cap

$4.4B

Day’s Range

$46.40 - $47.92

52wk Range

$30.04 - $78.48

Volume

44K

Avg Vol

1.9M

Gross Margin

-653467.24%

Why CRISPR could be a good low-risk move for the long run

CRISPR is incurring some significant losses, but its financial position hasn’t drastically worsened over the past year, as its working capital remains around $1.8 billion (as it was at the end of 2024). Meanwhile, the company has multiple projects in its pipeline that have potential, including CTX211, a treatment for Type 1 diabetes.

Overall, the stock is not as risky as other up-and-coming biotechs. CRISPR has an approved therapy in Casgevy that is still in its early growth stages, plus it has plenty of financial resources to help grow its business in other areas. At a market cap of around $4.6 billion, it may become a whole lot more valuable in the future. While I wouldn’t call it a bargain because there’s still some risk here, this is the type of mid-cap stock that may be worth taking a chance on, given its potential upside.